Value Analysis Committees for UVC and What They Need

EP: 1.FDA UV Authorization Introduction

EP: 2.When Did the FDA Begin Regulating UVC Robots?

EP: 3.What Separates Those Companies That Have Been FDA Authorized and Those That Haven’t?

EP: 4.Modalities to Study the Efficacy of UVC Devices

EP: 5.FDA’s UV Performance Testing and Emergency Use Authorization for the COVID-19 Pandemic

Now Viewing

EP: 6.Value Analysis Committees for UVC and What They Need

EP: 7.EPA Does Not Regulate Medical Devices, and UV Are Medical Devices

EP: 8.What Are the Differences Between Medical Devices and Nonmedical Devices?

EP: 9.Are These EPA-Regulated Since These Devices Are Dangerous to Staff?

EP: 10.What Is the Process to Get the FDA Authorization, and Is the FDA Enforcing this Industry?

EP: 11.Loopholes in the UV Device Industry

EP: 12.Where Can These Products Be Used if They Are Not (Yet) Authorized?

EP: 13.What Is Your One Piece of Advice to Health Care Leaders Evaluating These Devices?

EP: 14.Will the FDA Allow UV Companies to Market While Working on Getting the Authorization?

EP: 15.Educating the UV Device Purchaser

EP: 16.Panel Members’ Final Thoughts

Value Analysis Committees need hard data—not brochures—to judge whole-room UV systems. As Julie Mangino, MD, notes, the metrics that matter are post-manual-clean performance, workflow fit (staffing and runtime), and sustained utilization, verified with tools such as fluorescent markers and Adenosine Triphosphate (ATP) alongside real microbial reduction. The takeaway is to optimize basics first, then deploy UV emitters deliberately, track uptime and outcomes, and bring those numbers back to the committee so capital doesn’t wind up idle in a closet. The study Mangino mentions can be found here.